Visiongain Publishes Antiviral Drugs Treatment Market Report to 2031

22 February 2021
Pharma

Visiongain has published a new report on Antiviral Drugs Treatment Market Report to 2031. According to the Visiongain analysis, the global Antiviral Drugs Treatment market is anticipated to grow at a CAGR of XX% during the forecast period (2021-2031). The global Antiviral Drugs Treatment market is segmented By Application (HIV/AIDS , Influenza, Hepatitis (B & C), Herpes, Others, By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, Other) By End User (Hospitals, Clinics, Other) Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). The report includes detailed Profiles of Leading Antiviral Drugs Treatment Companies. PLUS COVID-19 Recovery Scenarios.

Global Antiviral Drugs Treatment Market was valued at US$XX billion in 2021 and is projected to reach a market value of US$ XX billion by 2031. The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market. The increasing prevalence of viral infections and presence of pipeline products for HIV treatment are some of the factors driving the growth of Antiviral Drugs Treatment market.

COVID-19 Impact on the Global Antiviral Drugs Treatment Market
The Coronavirus disease (COVID-19) is new virulent disease, growing transmission and fatal outcome in the global population. The COVID-19 is emerged as respiratory infection; However, the World Health Organization, Centers for Disease Control and Prevention, and the National Health Commission of the People’s Republic of China are taking action to reduce transmission and fatality associated with COVID-19. The COVID cases among older population are increasing rapidly; aging impacts both innate and adaptive arms of the immune system to impair control of viral infections.

Market Driver
Surging geriatric population

The older population is more susceptible to various viral infections, such as influenza, HIV, respiratory disease, the risk for severe infection from COVID-19 increases with age. The elderly are at high risk and needs hospitalization, intensive care, or a ventilator and are at high morbidity and mortality. The surging geriatric population, increase demand for antiviral drugs globally.

Increasing prevalence of viral infections

Increasing prevalence of infectious diseases such as HIV, Herpes, and Hepatitis B&C. HIV is major global public health issue. According to WHO there are approximately 38 million people across the globe in 2019. However, due to increasing access to the effective HIV prevention, diagnosis, treatment becomes manageable. The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) is the U.S. Government’s response to the global HIV/AIDS epidemic, which supported & secure from infectious disease threats. The rising prevalence of viral infection is significant factor to contribute the antiviral drugs treatment market.

Market Opportunity

Patent expiry of antiviral drugs boosts the market
Patent expiration expands marketing globally, making non-nucleoside reverse transcriptase inhibitors (NRTIs) popular first-line agents against HIV infections. Some major drugs reaching towards expiry includes Combivir, Sustiva, Tamiflu, Tenofovir, Telbivudine, and Relenza. The Sustiva, is a non-nucleoside transcriptase inhibitor, which incorporated into once-daily, fixed-dose, triple-drug therapy with tenofovir or emtricitabine. However, the patent expiries of these drugs, generate generic competition and enhance the global antiviral drug treatment market.

Competitive Landscape

F. Hoffmann-La Roche Ltd, Gilead Sciences Inc., Boehringer Ingelheim Corporation, AstraZeneca AB, GlaxoSmithKline, Novartis AG, Johnson & Johnson, Merck & Co, Aurobindo Pharma are some of the key players contributing to the growth of the global Antiviral Drugs Treatment market. The market players are adopting new strategies to stay competitive in the global market such as new product developments, joint ventures, mergers and acquisitions, and geographical expansions.

For instance, in November 2020, F. Hoffmann-La Roche Ltd announced that the European
Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Xofluza (baloxavir marboxil). It is recommended as preventive treatment post-exposure prophylaxis of influenza in individuals aged 12 years and above.

March 2020, Shionogi & Co., Ltd. announced that the company filed a Supplemental New Drug Application (sNDA) for Xofluza in Taiwan for the post exposure prophylaxis of influenza virus infection. The sNDA is based on data from the phase III BLOCKSTONE study; assessed Xofluza in the post-exposure prophylaxis of influenza virus infection. The approval of drug enables to reduce the burden of influenza in symptomatic and prophylactic treatment settings in Taiwan.

October 2018, F. Hoffmann-La Roche Ltd announced that the US Food and Drug Administration (FDA) has approved supplemental New Drug Application (sNDA) for Xofluza. The drug enables to treat acute, uncomplicated influenza, or flu, or patient with high risk of developing flu-related complications. Xofluza is oral medicine which inhibits polymerase acidic endonuclease.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Big Data Analytics in Healthcare Market Report 2021-2031

Healthcare has never been more personalized and affordable to anyone. Digital consulting applications use artificial intelligence to provide medical advice based on customized medical history record reviews and general medical information derived from big data inferences.

13 May 2021

Read

Visiongain Publishes NGS-Based RNA Sequencing Market Report 2021-2031

The market is expected to be driven by key factors such as rising cancer prevalence, government funding support in genetic research and technological advancements taking place in the biological research field. In addition, the market is predicted to gain huge traction in the developing countries.

11 May 2021

Read

Visiongain Publishes Single-Use Bioreactors Market Report 2021-2031

Strong product portfolio in the market is one of the major factors accelerating the growth of the market as availability of variants in the single-use systems allows targeted users more options.

11 May 2021

Read

Visiongain Publishes ePharmacy Market Report 2021-2031

The growth in online shopping has been driven by a rapid rise in the number of smartphones, broadband connections and innovative payment products, although security remains the biggest concern. With the evolving market dynamics, merchants’ payment needs are also changing.

06 May 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever